- In patients with relapsed or refractory classical Hodgkin lymphoma, pembrolizumab significantly improved PFS vs brentuximab vedotin across all subgroups.
Why this matters
- Pembrolizumab can become the new standard of care in these patients.
- Phase 3 KEYNOTE-204 trial.
- 304 patients with relapsed/refractory classic Hodgkin lymphoma were randomly assigned to receive either pembrolizumab or brentuximab vedotin.
- Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- Median follow-up: 24.7 months.
- Pembrolizumab significantly improved primary PFS vs brentuximab vedotin (median, 13.2 vs 8.3 months; HR, 0.65; P=.00271).
- 12-month PFS rates were 53.9% vs 35.6%, respectively.
- PFS benefit was observed in all subgroups:
- No post-autologous stem cell transplant (HR, 0.61).
- Primary refractory disease (HR, 0.52).
- Prior brentuximab (HR, 0.34).
- Brentuximab naive (HR, 0.67).
- Secondary PFS significantly improved with pembrolizumab (median, 12.6 vs 8.2 months; HR, 0.62; 95% CI, 0.46-0.85).
- In the pembrolizumab vs brentuximab vedotin group:
- Objective response rate was 65.6% vs 54.2%.
- Median duration of response was 20.7 vs 13.8 months.
- Grade 3-5 treatment-related adverse event (TRAE) rate was 19.6% vs 25.0%.
- 1 death was reported because of TRAE in the pembrolizumab group.
- Pneumonitis was more frequent with pembrolizumab.
- Open label.